Hence, these data highlight the key importance of Nrf2, HO-1 and GSH as molecular targets in order to sensitize high-risk neuroblastoma to proteasome inhibition obtained by using low doses of bortezomib, so improving the chance of an efficient therapeutic application of bortezomib as a sensitizing chemotherapeutic agent with low side-effects. Here, NFE2L2 is linked to neuroblastoma.